US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Time:2024-05-21 22:07:15 Source:entertainmentViews(143)
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
You may also like
- France is trying Syrian ex
- Traffic resumes near Copenhagen’s Old Stock Exchange after a fire ruined the 400
- Supreme Court will hear ghost guns case
- Japan's anti
- Pregnancy app used by the NHS accused of 'imposing gender ideology'
- Columbia cancels in
- Flooding wreaks havoc across East Africa. Burundi is especially hard
- 4 Germans caught marking Hitler's birthday outside Nazi dictator's birthplace in Austria
- Queen Camilla reveals she's seen the first season of Bridgerton